KR20240004275A - Sars-cov-2 mpro 억제제 화합물 - Google Patents

Sars-cov-2 mpro 억제제 화합물 Download PDF

Info

Publication number
KR20240004275A
KR20240004275A KR1020237033735A KR20237033735A KR20240004275A KR 20240004275 A KR20240004275 A KR 20240004275A KR 1020237033735 A KR1020237033735 A KR 1020237033735A KR 20237033735 A KR20237033735 A KR 20237033735A KR 20240004275 A KR20240004275 A KR 20240004275A
Authority
KR
South Korea
Prior art keywords
dimethyl
hexane
cyclopropyl
azabicyclo
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237033735A
Other languages
English (en)
Korean (ko)
Inventor
마일즈 스튜어트 콘그리브
존 앤드류 크로스토퍼
마크 픽워쓰
크라프 크리스 데
알리시아 페레즈 히구에루엘로
조나단 스테판 메이슨
Original Assignee
헵테얼즈 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104742.8A external-priority patent/GB202104742D0/en
Priority claimed from GBGB2107026.3A external-priority patent/GB202107026D0/en
Application filed by 헵테얼즈 테라퓨틱스 리미티드 filed Critical 헵테얼즈 테라퓨틱스 리미티드
Publication of KR20240004275A publication Critical patent/KR20240004275A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
KR1020237033735A 2021-04-01 2022-04-01 Sars-cov-2 mpro 억제제 화합물 Pending KR20240004275A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2104742.8A GB202104742D0 (en) 2021-04-01 2021-04-01 Sars-Cov-2 MPRO inhibitor compounds
GB2104742.8 2021-04-01
GB2107026.3 2021-05-17
GBGB2107026.3A GB202107026D0 (en) 2021-05-17 2021-05-17 SARS-COV-2 MPRO inhibitor compounds
PCT/GB2022/050836 WO2022208113A1 (en) 2021-04-01 2022-04-01 Sars-cov-2 mpro inhibitor compounds

Publications (1)

Publication Number Publication Date
KR20240004275A true KR20240004275A (ko) 2024-01-11

Family

ID=81307814

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033735A Pending KR20240004275A (ko) 2021-04-01 2022-04-01 Sars-cov-2 mpro 억제제 화합물

Country Status (7)

Country Link
US (1) US20240217930A1 (https=)
EP (1) EP4313305A1 (https=)
JP (1) JP2024511881A (https=)
KR (1) KR20240004275A (https=)
AU (1) AU2022247287A1 (https=)
CA (1) CA3213008A1 (https=)
WO (1) WO2022208113A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
GB202214644D0 (en) * 2022-10-05 2022-11-16 Heptares Therapeutics Ltd Sars-cov-2 mpro inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1385870T3 (da) * 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
EP4146267A1 (en) * 2020-05-08 2023-03-15 The Board of Trustees of the Leland Stanford Junior University Protease inhibitors for treatment or prevention of coronavirus disease

Also Published As

Publication number Publication date
EP4313305A1 (en) 2024-02-07
US20240217930A1 (en) 2024-07-04
JP2024511881A (ja) 2024-03-15
WO2022208113A1 (en) 2022-10-06
AU2022247287A1 (en) 2023-11-09
CA3213008A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
US20220259145A1 (en) Sars-cov-2 main protease inhibitors
KR20240004275A (ko) Sars-cov-2 mpro 억제제 화합물
US8211897B2 (en) Inhibitors of cathepsin B
EP4263502B1 (en) Sars-cov-2 mpro inhibitor compounds
GB2494851A (en) Plasma kallikrein inhibitors
SK286846B6 (sk) Peptidové analógy, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
US12060333B2 (en) Aminocarbamoyl compounds for the treatment of viral infections
WO2017151587A1 (en) Aza-peptide aldehydes and ketones
TW202330513A (zh) )抑制劑及其使用方法
JP2025533154A (ja) ＳＡＲＳ－ＣＯＶ－２Ｍｐｒｏ阻害剤及びその使用
US20230099089A1 (en) Antiviral substances with a wide spectrum of activity
WO2022066776A1 (en) Compositions and methods for treatment of coronavirus infection
CN117858867A (zh) Sars-cov-2 mpro抑制剂化合物
WO2024089159A1 (en) Main protease inhibitors
SK30394A3 (en) Derivatives of 2,4-diamino-3-hydroxycarboxylic acid, method of their preparation, pharmaceutical compositions containing these derivatives and their use
EP4587433A1 (en) 3-(1h-indole-2-carbonyl)-6,6-dimethyl-n-((s)-1-oxo-3-((s)-2-oxopyrrolidin-3-yl)p ropan-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide derivatives as mpro inhibitors for the treatment of coronavirus infections
US12583820B2 (en) Broad spectrum antivirals against coronavirus
CN117136178A (zh) SARS-COV-2 Mpro抑制剂化合物
HK40094156B (en) Sars-cov-2 mpro inhibitor compounds
HK40094156A (en) Sars-cov-2 mpro inhibitor compounds
JPH08259532A (ja) ペプチド様化合物又はその薬理的に許容される塩
EP1768665B1 (en) Peptidomimetic inhibitors of hiv protease
CN120923575A (zh) 一类拟肽类蛋白酶抑制剂及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231004

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250314

Comment text: Request for Examination of Application